Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 1
1980 1
1981 1
1984 1
1990 1
1994 2
1995 3
1996 2
1997 4
1998 3
1999 5
2000 3
2001 4
2002 6
2003 4
2004 7
2005 3
2006 7
2007 7
2008 6
2009 8
2010 12
2011 13
2012 16
2013 16
2014 19
2015 14
2016 23
2017 22
2018 28
2019 24
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

235 results
Results by year
Filters applied: . Clear all
Page 1
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.
BACKGROUND: The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell-related pain crises. ...Patients who were receiving concomi …
BACKGROUND: The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that …
Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease.
Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Badawy SM, et al. Pediatr Hematol Oncol. 2018 Aug-Sep;35(5-6):297-308. doi: 10.1080/08880018.2018.1505988. Epub 2019 Jan 12. Pediatr Hematol Oncol. 2018. PMID: 30636474 Clinical Trial.
BACKGROUND: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. ...More frequ …
BACKGROUND: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthca …
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells.
Grevet JD, Lan X, Hamagami N, Edwards CR, Sankaranarayanan L, Ji X, Bhardwaj SK, Face CJ, Posocco DF, Abdulmalik O, Keller CA, Giardine B, Sidoli S, Garcia BA, Chou ST, Liebhaber SA, Hardison RC, Shi J, Blobel GA. Grevet JD, et al. Science. 2018 Jul 20;361(6399):285-290. doi: 10.1126/science.aao0932. Science. 2018. PMID: 30026227 Free PMC article.
Increasing fetal hemoglobin (HbF) levels in adult red blood cells provides clinical benefit to patients with sickle cell disease and some forms of β-thalassemia. ...Taken together, these results suggest HRI as a potential therapeutic target for hemoglobinopathies
Increasing fetal hemoglobin (HbF) levels in adult red blood cells provides clinical benefit to patients with sickle cell disea …
Pain and sickle cell disease.
Aich A, Jones MK, Gupta K. Aich A, et al. Curr Opin Hematol. 2019 May;26(3):131-138. doi: 10.1097/MOH.0000000000000491. Curr Opin Hematol. 2019. PMID: 30893088 Review.
PURPOSE OF REVIEW: Pain is a major comorbidity of sickle cell disease (SCD). Opioids are the mainstay for pain treatment but remain suboptimal. ...Immunomodulatory components of acute and/or chronic sickle pain for targeting/preventing pain genesis include ma …
PURPOSE OF REVIEW: Pain is a major comorbidity of sickle cell disease (SCD). Opioids are the mainstay for pain treatment but r …
Mouse Models of Pain in Sickle Cell Disease.
Sagi V, Song-Naba WL, Benson BA, Joshi SS, Gupta K. Sagi V, et al. Curr Protoc Neurosci. 2018 Oct;85(1):e54. doi: 10.1002/cpns.54. Epub 2018 Sep 28. Curr Protoc Neurosci. 2018. PMID: 30265442
Sickle cell disease (SCD) is a genetic blood disorder that impacts millions of individuals worldwide. SCD is characterized by debilitating pain that can begin during infancy and may continue to increase throughout life. ...Humanized transgenic mice expressing exclus
Sickle cell disease (SCD) is a genetic blood disorder that impacts millions of individuals worldwide. SCD is characterized by
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Estcourt LJ, et al. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD003146. doi: 10.1002/14651858.CD003146.pub3. Cochrane Database Syst Rev. 2017. PMID: 28094851 Free PMC article. Review.
Sickle cell disease can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Stroke affects around 10% of children with sickle cell anaemia (HbSS). ...AUTHORS' CONCLUSIONS: There is no evidence for managing adu
Sickle cell disease can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Stroke
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, Goh AS, Huang V, Zia A, Herranz RM, Porter JB. Taher AT, et al. Health Qual Life Outcomes. 2018 Nov 19;16(1):216. doi: 10.1186/s12955-018-1041-5. Health Qual Life Outcomes. 2018. PMID: 30453981 Free PMC article. Clinical Trial.
Predictive factors of daily opioid use and quality of life in adults with sickle cell disease.
Karafin MS, Singavi A, Hussain J, Wandersee N, Heinrich T, Hurley RW, Zhang L, Simpson P, Field JJ. Karafin MS, et al. Hematology. 2018 Dec;23(10):856-863. doi: 10.1080/10245332.2018.1479997. Epub 2018 May 31. Hematology. 2018. PMID: 29848208 Clinical Trial.
OBJECTIVES: In adults with sickle cell disease (SCD), pain often necessitates opioid use. Few studies have examined the relationship between opioid use and health-related quality of life (HRQOL) in adults with SCD. ...Subject's questionnaire scores were compa …
OBJECTIVES: In adults with sickle cell disease (SCD), pain often necessitates opioid use. Few studies have examined the relati …
Targeting pain at its source in sickle cell disease.
Gupta K, Jahagirdar O, Gupta K. Gupta K, et al. Am J Physiol Regul Integr Comp Physiol. 2018 Jul 1;315(1):R104-R112. doi: 10.1152/ajpregu.00021.2018. Epub 2018 Mar 28. Am J Physiol Regul Integr Comp Physiol. 2018. PMID: 29590553 Free PMC article. Review.
Sickle cell disease (SCD) is a genetic disorder associated with hemolytic anemia, end-organ damage, reduced survival, and pain. ...In this review, we describe potential preventive/therapeutic targets and their targeting with novel pharmacologic and/or integrative ap
Sickle cell disease (SCD) is a genetic disorder associated with hemolytic anemia, end-organ damage, reduced survival, and pain
Physician knowledge and adherence to prescribing antibiotic prophylaxis for sickle cell disease.
Wurst KE, Sleath BL. Wurst KE, et al. Int J Qual Health Care. 2004 Jun;16(3):245-51. doi: 10.1093/intqhc/mzh033. Int J Qual Health Care. 2004. PMID: 15150156
OBJECTIVE: The purpose of this research was to examine how physician characteristics were associated with: (i). physician knowledge of and adherence to sickle cell guidelines; and (ii). the types of educational programs about sickle cell disease desire …
OBJECTIVE: The purpose of this research was to examine how physician characteristics were associated with: (i). physician knowledge of and a …
235 results
Jump to page
Feedback